News | February 06, 2026
Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Inspection included drug device combinations covering our recent filing in nasal sprays domain
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
Glucon-D maintained its leadership position with a 59% MAT market share
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Subscribe To Our Newsletter & Stay Updated
